Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today its
immunotherapy for hepatitis C (INO-8000) will be evaluated in a
phase I trial in chronically infected patients who are not
receiving other hepatitis C virus (HCV) treatments. The study will
enroll patients who are in the early stages of chronic HCV
infection to determine the therapy’s ability to decrease and
potentially eliminate HCV viral load, measure HCV specific immune
responses and durability of these immune responses, and evaluate
safety and tolerability. In this dose-escalation study INO-8000
will be combined with increasing doses of DNA-based IL-12
(INO-9012), an immune activator, which in previous studies has been
shown to increase the therapeutic immune response to DNA
immunotherapies.
The study is funded by the National Cancer
Institute’s Division of Cancer Prevention and will be conducted at
the Mayo Clinic and other U.S. sites.
Among those initially infected with HCV, 75 to
85 percent will go on to develop chronic illness. More than 170
million people around the world are chronically infected with HCV.
According to the U.S. Centers for Disease Control (CDC) an
estimated 3.5 million people in the US are chronically infected
with HCV, with about 20,000 new cases of chronic HCV reported in
the US in the last year. About 15,000 people in the US die each
year of HCV-related causes.
Inovio's SynCon® DNA immunotherapy, INO-8000, is
encoded for the antigens NS3/4A, NS4B, and NS5A of HCV genotypes 1a
and 1b, the most difficult-to-treat genotypes. The product is
designed to induce robust T cells to eliminate cells displaying
these antigens and has been shown in published preclinical studies
to generate powerful HCV-specific T cell responses throughout the
body and in the liver.
Dr. Jeffrey Jacobson, the study’s Principal
Investigator, said “Development of a vaccine therapy against
hepatitis C would be important as a less expensive, simpler
treatment alternative to several months of medication that should
encourage better patient compliance, particularly in
difficult-to-treat patient populations. It also holds the promise
of inducing immunity protective against re-infection in patients
who continue to be exposed, a not uncommon problem.” Dr. Jacobson
is Professor of Medicine, Neuroscience and Neurovirology at the
Lewis Katz School of Medicine, Temple University.
Dr. J. Joseph Kim, President and CEO, said,
“Despite recent treatment advances, HCV infection remains a burden
on our healthcare and payor system and continues to spread. Today’s
expensive drugs are highly effective in treating HCV but are not
available to the majority of infected individuals. We are pleased
to join the NCI and Mayo Clinic in this quest to develop an
alternative medical solution to fight this disease, which remains
one of the fastest-developing markets in healthcare."
Inovio previously announced that it signed a
collaborative agreement with GeneOne Life Sciences to develop
INO-8000, along with a DNA IL-28 immune activator, in
drug-resistant HCV patients in a phase I study in Korea. That study
is on-going.
About Hepatitis C
Hepatitis C is a contagious liver disease that
ranges in severity from a mild illness lasting a few weeks to a
serious lifelong illness that attacks the liver. It results from
infection with the hepatitis C virus, which is spread primarily
through contact with the blood of an infected person. Hepatitis C
can be either "acute" or "chronic." Acute hepatitis C virus
infection is a short-term illness that occurs within the first six
months after someone is exposed to the virus. For most people,
acute infection leads to chronic infection, which can last a
lifetime and lead to serious liver problems including cirrhosis
(scarring of the liver) or liver cancer.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, Roche, The Wistar Institute, University of Pennsylvania,
DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines
Trial Network, National Cancer Institute, U.S. Military HIV
Research Program, and University of Manitoba. For more information,
visit www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines, our expectations regarding our research and development
programs and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100 and
INO-3112, that pre-clinical studies and clinical trials may not
commence or be completed in the time periods anticipated, that
results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results
from an animal study may not be indicative of results achievable in
human studies), the availability of funding to support continuing
research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop
viable DNA vaccines, our ability to support our broad pipeline of
SynCon® active immune therapy and vaccine products, our ability to
advance our portfolio of immune-oncology products independently,
the ability of our collaborators to attain development and
commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by the company or its collaborators, including
alternatives that may be more efficacious or cost-effective than
any therapy or treatment that the company and its collaborators
hope to develop, our ability to enter into partnerships in
conjunction with our research and development programs, evaluation
of potential opportunities, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide the company with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K for
the year ended December 31, 2015, and other regulatory filings from
time to time. There can be no assurance that any product in
Inovio's pipeline will be successfully developed or manufactured,
that final results of clinical studies will be supportive of
regulatory approvals required to market licensed products, or that
any of the forward-looking information provided herein will be
proven accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024